Mobile website
Cancer targeting gene-viro-therapy: An evolving anti-cancer strategy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
The author proposed the concept of cancer targeting gene-viro-therapy (CTGVT) in 2001. By inserting an anti-tumor gene into an oncolytic virus (OV), this novel approach combines the advantages of both gene therapy and OV therapy. The anti-tumor effect of CTGVT can be several dozens to hundred times higher than that of either respective cancer gene therapy or OV therapy alone, owing to the fact that OV can target to the cancer cell where both the virus and the inserted gene replicate several tens or hundreds of times faster than usual. Given compensatory or synergetic effects of genes, double gene strategy (CTGVT-DG) has been demonstrated in an animal model of xenograft tumor to be significantly more effective. In our approaches, the OncoAd vector is used. To minimize the OV injection-associated vector degradation, we choose to coat the CTGVT-DG products with nano-particles or to use the OncoPox vector. In the previous studies from the Western countries, only the immune effect of GM-CSF is considered in the OV-Gene system, while the replicative capacity of the gene is often ignored. As a result, our strategies may be able to more effectively eradicate tumors, thereby offering greater clinical potential.
Keywords:
Project Supported:
Project supported by the National Basic Research Development Program of China (973 Program)（No. 2011CB510104），the General Program of National Natural Science Foundation of China（No. 81372453），and the Natural Science Foundation of Shanghai City（No. 13ZR1446300）
Clc Number:
